Endo International | ENDP - Beneficio Bruto En Ventas



Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 143.88M 19.7M 2026-03
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 16.22B 301.7M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Ligand Pharmaceuticals USD 100.41M 51.96M 2026-06
Merck USD 12.09B 1.24B 2026-03
Novartis USD 11.24B 1.18B 2026-06
Pacira USD 133.91M 7.27M 2026-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Phibro Animal Health USD 133.5M 12.6M 2025-12
Supernus Pharmaceuticals USD 160.06M 30.7M 2026-06
Takeda JPY 813.22B 124.39B 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Xeris Pharmaceuticals USD 72.55M 404K 2026-03
Zoetis USD 1.76B 140M 2026-06